208 related articles for article (PubMed ID: 31874280)
1. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment.
La-Beck NM; Liu X; Shmeeda H; Shudde C; Gabizon AA
Semin Cancer Biol; 2021 Jan; 68():175-185. PubMed ID: 31874280
[TBL] [Abstract][Full Text] [Related]
2. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
4. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
Massey AS; Pentlavalli S; Cunningham R; McCrudden CM; McErlean EM; Redpath P; Ali AA; Annett S; McBride JW; McCaffrey J; Robson T; Migaud ME; McCarthy HO
Mol Pharm; 2016 Apr; 13(4):1217-28. PubMed ID: 26954700
[TBL] [Abstract][Full Text] [Related]
5. Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model.
Islam MR; Patel J; Back PI; Shmeeda H; Kallem RR; Shudde C; Markiewski M; Putnam WC; Gabizon AA; La-Beck NM
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759709
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
7. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
8. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.
Rajan R; Sabnani MK; Mavinkurve V; Shmeeda H; Mansouri H; Bonkoungou S; Le AD; Wood LM; Gabizon AA; La-Beck NM
J Control Release; 2018 Feb; 271():139-148. PubMed ID: 29277680
[TBL] [Abstract][Full Text] [Related]
9. Nitrogen-containing bisphosphonates and cancer immunotherapy.
Clézardin P; Massaia M
Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
Clézardin P
Bull Cancer; 2010 Aug; 97(8):937-49. PubMed ID: 20595092
[TBL] [Abstract][Full Text] [Related]
13. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in the treatment of metabolic bone diseases.
Rodan GA; Balena R
Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
Okada S; Kiyama T; Sato E; Tanaka Y; Oizumi T; Kuroishi T; Takahashi T; Sasaki K; Sugawara S; Endo Y
Tohoku J Exp Med; 2013 Oct; 231(2):145-58. PubMed ID: 24140868
[TBL] [Abstract][Full Text] [Related]
17. Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells.
Zlatev HP; Auriola S; Mönkkönen J; Määttä JA
Eur J Pharm Sci; 2016 Apr; 86():58-66. PubMed ID: 26957415
[TBL] [Abstract][Full Text] [Related]
18. Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study.
Forte L; Torricelli P; Boanini E; Gazzano M; Fini M; Bigi A
Acta Biomater; 2017 May; 54():419-428. PubMed ID: 28238916
[TBL] [Abstract][Full Text] [Related]
19. [Development of bisphosphonates].
Nakatsuka K
Nihon Rinsho; 2003 Feb; 61(2):219-25. PubMed ID: 12638211
[TBL] [Abstract][Full Text] [Related]
20. Rationale for the use of alendronate in osteoporosis.
Kanis JA; Gertz BJ; Singer F; Ortolani S
Osteoporos Int; 1995 Jan; 5(1):1-13. PubMed ID: 7703618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
